114 related articles for article (PubMed ID: 37802206)
21. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.
Li H; Cui ML; Chen TY; Xie HY; Cui Y; Tu H; Chen FH; Ge C; Li JJ
Tumour Biol; 2015 Nov; 36(11):8399-404. PubMed ID: 26018510
[TBL] [Abstract][Full Text] [Related]
22. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection.
Jin J; Zhu P; Liao Y; Li J; Liao W; He S
Oncotarget; 2015 Aug; 6(22):19217-27. PubMed ID: 26057470
[TBL] [Abstract][Full Text] [Related]
23. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
24. IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma.
Wu Y; Cheng G; Chen H; Wang J; Wang J; Wang W
Clin Hemorheol Microcirc; 2021; 77(1):37-47. PubMed ID: 32651310
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion.
Dou W; Yang M; Su Y; Xie R
Diagn Pathol; 2020 May; 15(1):54. PubMed ID: 32404179
[TBL] [Abstract][Full Text] [Related]
26. Twist Expression in Circulating Hepatocellular Carcinoma Cells Predicts Metastasis and Prognoses.
Yin LC; Luo ZC; Gao YX; Li Y; Peng Q; Gao Y
Biomed Res Int; 2018; 2018():3789613. PubMed ID: 30046595
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma.
Shi J; Wang Y; Wang F; Zhu Z; Gao Y; Zhang Q; Du Z
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):855-864. PubMed ID: 32205116
[TBL] [Abstract][Full Text] [Related]
28. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].
Zhang PR; Ma XL; Guo L; Lu RQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):885-890. PubMed ID: 37357208
[No Abstract] [Full Text] [Related]
29. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.
Ikai I; Arii S; Kojiro M; Ichida T; Makuuchi M; Matsuyama Y; Nakanuma Y; Okita K; Omata M; Takayasu K; Yamaoka Y
Cancer; 2004 Aug; 101(4):796-802. PubMed ID: 15305412
[TBL] [Abstract][Full Text] [Related]
30. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
Guo ZY; Zhu ZT
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
[TBL] [Abstract][Full Text] [Related]
31. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation.
Ng KT; Lo CM; Wong N; Li CX; Qi X; Liu XB; Geng W; Yeung OW; Ma YY; Chan SC; Man K
Oncotarget; 2016 Apr; 7(15):19824-39. PubMed ID: 26918346
[TBL] [Abstract][Full Text] [Related]
32. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.
Liu K; Ding Y; Wang Y; Zhao Q; Yan L; Xie J; Liu Y; Xie Q; Cai W; Bao S; Wang H
Clin Exp Med; 2023 Jun; 23(2):397-409. PubMed ID: 35347503
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim SH; Chung YH; Yang SH; Kim JA; Jang MK; Kim SE; Lee D; Lee SH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Suh DJ
Korean J Hepatol; 2009 Sep; 15(3):320-30. PubMed ID: 19783881
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
35. [A preliminary discussion on carnosine dipeptidase 1 as a potential novel biomarker for the diagnostic and prognostic evaluation of hepatocellular carcinoma].
Li X; Li Y; Li X; Jiang LN; Zhu L; Lu FM; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):627-633. PubMed ID: 37400388
[No Abstract] [Full Text] [Related]
36. Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after orthotopic liver transplantation by promoting cancer metastasis and recurrence.
Huang Y; Yang X; Zhao F; Shen Q; Wang Z; Lv X; Hu B; Yu B; Fan J; Qin W
Med Oncol; 2014 Jul; 31(7):966. PubMed ID: 24878698
[TBL] [Abstract][Full Text] [Related]
37. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma.
Lee YR; Kim G; Tak WY; Jang SY; Kweon YO; Park JG; Lee HW; Han YS; Chun JM; Park SY; Hur K
Int J Cancer; 2019 Mar; 144(6):1444-1452. PubMed ID: 30338850
[TBL] [Abstract][Full Text] [Related]
38. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma.
Xu L; Zhang M; Zheng X; Yi P; Lan C; Xu M
J Cancer Res Clin Oncol; 2017 Jan; 143(1):17-27. PubMed ID: 27614453
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma.
Chen W; Chen L; Cai Z; Liang D; Zhao B; Zeng Y; Liu X; Liu J
Tumour Biol; 2016 Jul; 37(7):9343-55. PubMed ID: 26779633
[TBL] [Abstract][Full Text] [Related]
40. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
